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transformed fibroblasts are sensitive to cisplatin
and UVB induced apoptosis and show aberrant
expression of p53
Margaret Finlay1, ZhengQiang Yuan2, Iain M Morgan1, M Saveria Campo1 and Lubna Nasir1*Abstract
Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of
commonly occurring equine sarcoid tumours. Whilst treatment of sarcoids is notoriously difficult, cisplatin has been
shown to be one of the most effective treatment strategies for sarcoids. In this study we show that in equine
fibroblasts, BPV-1 sensitises cells to cisplatin-induced and UVB-induced apoptosis, a known cofactor for
papillomavirus associated disease, however BPV-1 transformed fibroblasts show increased clonogenic survival, which
may potentially limit the therapeutic effects of repeated cisplatin treatment. Furthermore we show that BPV-1
increases p53 expression in sarcoid cell lines and p53 expression can be either nuclear or cytoplasmic. The
mechanism and clinical significance of increase/abnormal p53 expression remains to be established.Introduction
Sarcoids are the most common skin tumours to affect
equids worldwide [1-3] with reported prevalence rates
ranging from 0.5% to 2.0% [4,5]. Recently, high preva-
lence rates (25-53%) have been reported in two popula-
tions of inbred zebras [6]. Equine sarcoid affects horses
of all ages, breeds and colour with no sex predilection.
Six clinical types of sarcoids are recognised including oc-
cult, verrucose, nodular, fibroblastic, mixed and malig-
nant types [7].
Treatment of sarcoid is notoriously difficult and cur-
rently there is no effective treatment for sarcoids that
cures without recurrence [7-9]. Surgery is often used but
has a high failure rate due to tumour recurrence [8]. As
a result of the difficultly in treating sarcoids, there are a
variety of treatment options that have been used in clin-
ical practice including cryosurgery [10] laser surgery
[11], BCG immunotherapy [12], intratumoral chemo-
therapy and topical formulations including zinc chloride* Correspondence: Lubna.Nasir@gla.ac.uk
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reproduction in any medium, provided the orcream [13] imiquimod [14] or aciclovir [15]. The success
of therapy appears to depend on several factors includ-
ing site and size of the tumour, type of sarcoid and num-
ber of lesions [16,17]. Furthermore, it is generally
accepted that prognosis for treatment is worse if one or
more unsuccessful treatment attempts have previously
been made [16].
It is now well established that equine sarcoids are
caused by infection with Bovine Papillomaviruses (BPV)
types 1 and 2 [18]. BPV-1/2 are non-enveloped double
stranded DNA viruses with a genome of approximately
8kbp that infect their natural host, cattle, causing papil-
lomas of skin or mucosa which generally regress without
eliciting any serious clinical problems in the host [19].
None of the treatment strategies for sarcoids directly tar-
get the viral infection, although vaccine studies in vivo
have been successful [20] and in vitro studies to knock
down viral DNA expression are very effective in prevent-
ing growth of sarcoid fibroblasts [21,22]. Recently we
have developed a panel of BPV-1 transformed equine
cell lines as model systems for studying the pathogenesis
of equine sarcoids [23], and these lines have proved
invaluable in our understanding of sarcoid disease
pathogenesis [21-28]. Using these cell lines, in thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the chemotherapeutic agents cisplatin and the effects
of Ultraviolet B (UVB). Cisplatin has been shown to be
one of the most effective treatment strategies for sar-
coids with success rates close to 100% [29-31]. Cisplatin
causes cross-links in DNA, leading to DNA functional
abnormalities culminating in the initiation of cell death
via caspases [32] by activation of mitogen-activated pro-
tein kinase (MAPK) signaling pathway [33]. UV is a
known cofactor for PV associated disease [34] and
whilst there is no evidence that UVB is involved in
equine sarcoid pathogenesis, previous studies have
shown that papillomaviral proteins can inhibit UV in-
duce apoptosis [35].Materials and methods
Cell culture
Normal equine embryonic fibroblast line EqPalF, BPV-1
in vitro transformed EqPalF (S6-1, S6-2, S6-3), sarcoid
cell lines EqS01a, EqS02a, EqS03a and EqS04b have dif-
fering viral loads and viral gene expression levels and
have been described previously [23]. EqS03a and EqS013
are new sarcoid derived cell lines generated as described
previously [23]. Cells were maintained in culture in
complete DMEM in a 37°C humidified atmosphere of
5% CO2 in air.Sarcoid tissue samples
Sarcoid tumour samples were collected with informed
owner consent from cases presented at the Weipers
Centre for Equine Welfare, University of Glasgow and at
the Liverpool University Equine Hospital.Apoptosis
To assess apoptosis, cells were double-stained with
FITC-Annexin V and propidium iodide (PI) using
the Annexin V Apoptosis Detection kit (Darmstadt,
Germany), according to the manufacturer’s recommen-
dations. Cells were assessed 24 h post UVB treatment
(Ultaviolet transilluminator, Sigma, Dorset, UK; 250
and 500 mJ/cm2). Cells were incubated with cisplatin
(10 μg/mL and 25 μg/mL, Hospira, Warickshire, UK)
for 72 h and then assessed for apoptosis. All cells were
analyzed on an Epics XL Flow Sorter (Beckman-
Coulter, High Wycombe, UK). For analysis, the cells
were divided into four distinct populations using the
control cells as a reference: costaining with Annexin V
and PI allows differentiation of viable non apoptotic
cells (Annexin V−, PI−) from early apoptotic cells
(Annexin V+, PI−) and late apoptotic cells (Annexin V+,
PI+). The cells in each quadrant were gated, and the
percentage of the total cell population was determined.Clonogenic survival assays
Following exposure of cells to either UVB or cisplatin
(described above), approx 5 × 103 cells were washed and
suspended in fresh medium and then serial dilutions
were plated onto methylcellulose-containing medium.
Ten days later, the cells were fixed and stained with 10%
methylene blue in 70% ethanol. The number of colonies
were counted, and the surviving fraction was calculated
as the ratio of the number of colonies in the treated
sample to the number of colonies in the untreated sam-
ple. All tests were performed in triplicate.
P53 expression
To assess endogenous and DNA damage-induced
stabilization of p53, cells were plated at 8 × 105 in
10 cm2 petri dishes and were irradiated with UV light at
250 J/m2 and harvested 4 h post UV treatment. Cells
were lysed by the addition of 500 μL of 2 × SDS sample
buffer. Samples were boiled, analyzed by SDS–10%
PAGE, and assessed by Western blotting using human
p53 D0-7 antibody (DO-7 p53 clone; Novocastra Milton
Keynes, UK diluted 1:200 in 10 mM Tris Buffer Saline
(TBS) using standard methods. Filters were stripped and
reprobed with GAPDH antibody (V-18 Novacastra) to
control for protein loading. To assess the transcriptional
activation function of p53, cells were irradiated with
UV light at 30 J/m2 and harvested ~10 h post UV
treatment for assessment of p21 expression (C-19,
Novacastra). The half-life of the p53 protein was deter-
mined following culturing of cells with or without
cyclohexamide (40 μg/mL, 48 h) at 37°C. Cells were
harvested at various time points (0, 0.5, 1, 3, 5 h) and
assessed for p53 protein expression by western blot
analysis using D0-7 antibody. Quantification of expres-
sion levels was carried out by using NIH ImageJ Soft-
ware analysis (NIH, Maryland, USA).
The assessment of p53 protein expression in sarcoid tis-
sue sections or cells grown on 8-well chamber slides was
performed using a two-step immunohistochemical tech-
nique using Dako EnVision kit (K4007, Cambridgeshire,
UK) following the manufacturer’s instructions using D0-7
p53 antibody (1:400). For negative controls, duplicate
slides were incubated with a non-related serum instead of
the p53 primary antibody.
Results
BPV-1 confers increased sensitivity to UVB and cisplatin
induced apoptosis
To determine whether expression of BPV-1 can influ-
ence apoptosis, BPV-1 transformed EqPalF cells
(S6 cells), control EqPalF cells and a panel of sarcoid
derived cell lines (EqS) were exposed to UVB and cis-
platin followed by quantitative assessment by FACs ana-
lysis. Firstly, cells were exposed to UVB irradiation (250,
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http://www.veterinaryresearch.org/content/43/1/81500 mJ/cm2) and apoptosis assessed 24 h post irradi-
ation (Figure 1a). An increase in cell apoptosis was
detected in S6 cells compared to the parental cell line
which lacks BPV-1 (EqPalF), indicating that BPV-1 con-
fers sensitivity to UVB induced apoptosis. An increase in
cell apoptosis was also detected in sarcoid derived
tumour lines (Figure 1a). The same panel of cell lines
were treated with cisplatin (10, 25 μg/mL) for 72 h. A
significant increase in apoptosis was observed in S6 cells
(Figure 1b) demonstrating that BPV-1 sensitises cells to
cisplatin induced apoptosis. Increased apoptosis was also
detected in sarcoid derived tumour lines in the presence0.0
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Figure 1 Cisplatin and UVB induced apoptosis. Levels of apoptosis dete
sarcoid cell lines (EqS cells) following treatment with (a) UVB (b) cisplatin. R
performed in triplicate. *indicates significance (p < 0.05).of 10 μg/mL cisplatin but not at a higher dose
(Figure 1b). The sensitivity to UVB and cisplatin induced
apoptosis is independent of viral load or viral gene
expression.
BPV-1 increases clonogenic survival following exposure to
DNA damaging agents
To determine the sensitivity/resistance of BPV trans-
formed cells to the cytotoxic effects of DNA damaging
agents following exposure to DNA damaging agents,
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Figure 2 Clongenic survival following cisplatin and UVB
exposure. Clonogenic survival of control (EqPaLF), BPV-1
transformed EqPalFs (S6 cells) and sarcoid cell lines (EqS cells)
following treatment with cisplatin and UVB. The surviving fraction is
the ratio of the number of colonies in the treated sample to the
number of colonies in the untreated sample. All tests were
performed in triplicate. *indicates significance (p < 0.05).
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increased clonogenic survival than control cells (Figure 2).
Similarly following cisplatin (10 μg/mL) treatment, the
majority of cell lines showed increased cell survival
(Figure 2).BPV-1 increases p53 expression
Since UVB and cisplatin can induce apoptosis via p53
dependent pathways, we next sought to address the
expression levels of p53 in the cell lines. p53 protein
expression was compared by Western blot analysis using
D0-7 antibody in the control cell line EqPalF, two BPV-1
transformed cell lines (S6-2 and S6-3) and two sarcoid
derived cell lines (EqS02a and EqS04b). As shown in
Figure 3a, all BPV-1 cell lines examined showed higher
levels of p53 protein expression compared to control
EqPalF cells (which express negligible/very low levels of
p53) and UVB exposure further increased p53 expression.
These data demonstrate that p53 expression is increased
by BPV-1 and that UVB increases p53 (Figure 3a).Eq
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Figure 3 P53 expression. a. UVB induced p53 expression in control (EqPa
cells). b. p53 protein half-life in control EqPalF and EqS04b cells.To establish whether the increased levels of p53 ex-
pression in BPV-1 fibroblasts compared to EqPalFs was
due to increased stability, EqS04b cells were treated with
cyclohexamide to block protein synthesis and p53 ex-
pression examined at various time points. As shown in
Figure 3b, p53 expression remained unchanged in
EqS04b cells whereas it diminishes over time in control
cells. This suggests that p53 upregulation in BPV-1 cells
is due to enhanced p53 stability.
To further investigate the expression pattern of p53,
Immunocytochemistry (ICC) was performed prior to
and following UVB irradiation in two sarcoid derived
cell lines (EqS01a, EqS04b) and the BPV-1 negative
line. EqPalFs did not express any detectable p53 by
ICC, however following UVB exposure, p53 protein ex-
pression was induced in the nuclei of cells (Figure 4).
EqS01a cells showed detectable nuclear p53 expression
in the absence of UVB and the percentage of positive
cells increased following UVB exposure (Figure 4).
These results are in agreement with the western blot
data. In contrast, EqS04b cells showed a distinct
punctate cytoplasmic pattern with no nuclear stain-
ing evidence (Figure 4). The levels of cytoplasmic p53
expression following UV irradiation also increased in
these cells (Figure 4), in agreement with the Western blot
data. Since this pattern of p53 expression was unex-
pected, we performed ICC on further cell lines and a
similar staining pattern was observed for cell line EqS013
(Figure 5a). The original tumour sample from which the
cell line EqS013 was derived was also examined for p53
expression and cytoplasmic staining was clearly evident
in the tumour biopsy (Figure 5b) indicating that the aber-
rant p53 expression is not a result of cell culture.
P53 expression in vivo
To establish whether there was any association between
levels of p53 expression and the clinical type of sarcoid, 39
sarcoid tumours were subjected to Immunohistochemistry
(IHC) using the D0-7 antibody. The results are presented
in Table 1. Of the 39 sarcoids tested, 17 (43%) were posi-
tive for nuclear p53 expression and most p53 positive
tumours were fibroblastic or nodular tumour types.p53
GAPDH 
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Figure 4 Immunohistochemical detection of p53. P53 expression prior to and following UVB exposure.
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Currently, there is no universally effective therapy for
the treatment of sarcoids which remains a major clinical
challenge. The efficacy of different treatments is difficult
to assess because most studies have not been designed
to include controls and are frequently based on referral
populations of horses treated at veterinary hospitals
[5,36,37]. In the present study we have examined the ef-
ficacy of two DNA damaging agents to induce apoptosis.
Our data show that BPV-1 cells are more sensitive to
the apoptotic effects of both UVB and cisplatina b
Figure 5 Cytoplasmic expression of p53. Cytoplasmic/perinuclear p53 st
derived.compared control cells. UVB reduces the half-life of E2
[38]; and we have shown that loss of BPV-1 E2 leads to
increased apoptosis [21] which may explain this finding.
The BPV-1 mediated sensitisation to cisplatin may ex-
plain the relatively good success rates and low toxicity
reported with cisplatin in equine sarcoids; Theon et al.,
demonstrated cisplatin to be effective over a two year
period in 90% of cases [29,39,40]; Hewes and Sullins [30]
have reported an 85% success rate in equine sarcoids
after a 2 year follow-up. Despite the increased apoptosis
detected, BPV-1 cells are better able to survive the DNAaining in EqS013 cells and the tumour from which the cell line was
Table 1 Levels of p53 immunoreactivity in different
clinical sarcoid types
p53 expression Fibroblastic Nodular Verrucose Mixed Total
neg 3 10 3 6 22
low 1 1 0 2 4
med 3 4 0 0 7
high 5 1 0 0 6
12 16 3 8 39
(Low = 0-10% cells positive, Med = 10-20% cells positive, High > 20% cells
positive).
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small subset of resistant clones and the repeated use of
cisplatin may therefore select for cells that are particu-
larly resistant to apoptosis suggesting that cisplatin may
not be appropriate for repeated treatment of sarcoids.
We have shown that p53 is overexpressed in BPV-1
cell lines. The p53 tumor suppressor protein plays a
key role in coordinating cell cycle arrest, DNA repair,
and programmed cell death following DNA damage
[41]. P53 protein is relatively unstable and has a short
half-life, and is usually undetectable in normal cells by
immunohistochemistry [42]. In contrast, overexpression
of p53 is often associated with the presence of mutant
p53, which has a longer half life. However, there is no
evidence to date for the presence of p53 gene muta-
tions in equine sarcoids [43,44] and our sequence ana-
lysis of EqS04b cells demonstrates wild type p53 (data
not shown), although the possibly of p53 gene muta-
tions in the other cell lines cannot be ruled out. Over-
expression of wild type p53 has been observed in
tumours [45,46] and whilst the reason for this or its
biological significance is not known, several studies
have shown that it may be due to changes in the func-
tionality of proteins that interact and control the activ-
ity and the levels of p53, such as MDM2 [47] and
MDMX [48]. It has also been suggested that the over-
expression may be a result of downregulation of ubi-
quitin mediated proteasome degradation [49]. We
show that the overexpression of wild type p53 in
EqS04b cells is (at least in part) due to abnormal p53
stability however further studies are necessary to
understand the mechanisms involved and the clinical
significance. In HPV, p53 expression is stabilised by
the E7 oncoprotein [50].
We show that in 2 sarcoid derived cell lines (EqS04b,
EqS013) p53 overexpression is cytoplasmic. Cytoplasmic
sequestration of p53 has been proposed as an important
mechanism to disrupt its function as a tumor suppressor
and has been reported in a range of tumours including
breast cancers and neuroblastomas [51,52]. Cytoplasmic
sequestration of wild type correlates with attenuation of
DNA damage-induced G1 arrest [53] and apoptosis inneuroblastoma cell lines [54]. Several factors are known
to induce p53 cytoplasmic localisation including Jab1,
which facilitates p53 nuclear exclusion and degradation
[55] and, Parc, a parkin-like ubiquitin ligase, has recently
been shown to function as cytoplasmic anchor protein
of p53 [56]. The pattern of cytoplasmic staining seen in
this study using the D0-7 antibody in EqS04b cells is
very different from the disperse uniform cytoplasmic
staining of the cytoplasm we have previously observed
with CM-1 antibody [23]. In fact, in our previous study,
CM-1 antibody showed cytoplasmic staining in EqS01a
and S6-2 cells but not in control EqPalFs, however with
the D0-7 antibody expression is clearly nuclear and ex-
pression is induced following UV exposure. These data
suggest that CM-1 antibody and D0-7 antibody may rec-
ognise different forms of p53; additionally it appears that
D0-7 antibody is best able to recognise equine p53
[57,58]. We and others have previously shown that a
subset of equine sarcoid tumours express cytoplasmic
p53 [57-60] We have also shown that in an equine sar-
coid derived cell line sarc-1 with cytoplasmic p53, no
mRNA expression of the p53 target gene, mdm2 could
be detected either before or after UV treatment [60]
showing that p53 transcriptional activation function is
compromised in cells with cytoplasmic p53. The aber-
rant expression of p53 may also contribute to the
increased clonogenic survival following DNA damage in-
sult, but this speculative and remains to be established.
Our preliminary analysis of p53 expression and clinical
type of sarcoid shows that more sarcoid aggressive sar-
coids (fibroblastic and nodular) have higher levels of p53
positivity than quiescent verrucose sarcoids. However,
the numbers of samples in this study are small and fur-
ther studies are warranted to substantiate this initial
finding.
In summary, we show that BPV-1 transformed
equine fibroblasts are more sensitive to the apoptotic
effects of cisplatin and UVB than control cells but
show increased clonogenic survival. We show that in
sarcoid cell lines, BPV-1 increases p53 expression
within the nucleus but in some cell lines, p53 expres-
sion is cytoplasmic.Competing interests
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